Eisai lowers Leqembi revenue forecast after rocky entry to market
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
What's Your Reaction?
